Abstract: The present invention discloses a new and improved process for the preparation of sameridine and its pharmaceutically acceptable salt.

Abstract: An imidazopyridine derivative of the formula ?I!: ##STR1## wherein R.sup.1 is a lower alkyl group, R.sup.2 is a lower alkanoyl group, and R.sup.3 and R.sup.4 are each lower alkyl groups, or both combine at the end thereof to form an alkylene group having 3 to 6 carbon atoms, and a pharmaceutically acceptable salt thereof, said imidazopyridine derivatives have an excellent angiotensin II antagonistic activity and are useful for the prophylaxis or treatment of hypertension.

Abstract: An integrated circuit structure including dielectric barrier layer compatible with perovskite ferroelectric materials and comprising zirconium titanium oxide, ZrTiO.sub.4, and a method of formation of the dielectric barrier layer by sol gel process is described. The amorphous, mixed oxide barrier layer has excellent dielectric properties up to GHz frequencies, and crystallizes above 800.degree. C., facilitating device processing. In particular, the barrier layer is compatible with lead containing perovskites, including PZT and PLZT ferroelectric dielectrics for example for application in non-volatile memory cells, and high value capacitors for integrated circuits, using silicon or GaAs integrated circuit technologies.

Abstract: The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

Abstract: The invention relates to new quinolone- and naphthyridonecarboxylic acid derivatives which are substituted in the 7-position by a tricyclic amine radical, their salts, processes for their preparation and antibacterial compositions comprising these compounds.

Abstract: Substituted benzyloxycarbonylguanidines, a process for their preparation, their use as a medicament or diagnostic, and a medicament containing them. There are described compounds of the formula I ##STR1## in which the substituents R(1) to R(7) and X have the meanings shown in the claims, and their pharmaceutically tolerable salts. These are effective inhibitors of the cellular sodium proton antiporter (Na.sup.+ /H.sup.+ exchanger). They are therefore outstandingly suitable for the treatment of all diseases which can be attributed to increased Na.sup.+ /H.sup.+ exchange.

Abstract: This invention concerns a compound of generic formula: ##STR1## or a pharmaceutically acceptable salt thereof, where the dotted lines represent optional bonds,R.sup.3 is an optionally substituted C.sub.6 -C.sub.10 aryl or heteroaryl group; optionally substituted by one or more substituents the same or different,R' represents one or more optional substituents the same or different, selected from the following: halogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.7 alkoxycarbonyl, C.sub.1 -C.sub.6 hydroxyalkyl, CN, aminocarbonyl, C.sub.2 -C.sub.7 alkanoyloxy(C.sub.1 -C.sub.6 )alkyl, carboxy, C.sub.2 -C.sub.7 alkanoxylamino, optionally substituted C.sub.6 -C.sub.10 or heteroaryl or an optionally substituted (C.sub.6 -C.sub.10 aryl)alkyl or a heteroaryl alkyl radical; andR" represents one or more optional mono- or di- valent substituents in the 5, 7 or 8 positions the same or different: monovalent substituents being selected from the following: C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.7 alkanoyloxy, hydroxy, amino, C.

Abstract: The subject invention provides for novel compounds for inactivating viruses. These compounds include 6-nitroso-1,2-benzopyrone, 3-nitrosobenzamide, 5-nitroso-1 (2H)-isoquinolinone, 7-nitroso-1(2H)-isoquinolinone, 8-nitroso-1 (2H)-isoquinolinone. The invention also provides for compositions containing one or more of the compounds, and for methods of treating viral infections, cancer, infectious virus concentration with the subject compounds and compositions.

Abstract: Benzly-piperidine derivatives of formula I and their pharmaceutically acceptable salts are used in the control of psychotic disorders which are caused by damage to the dopamine system, especially schizophrenia. ##STR1## A is ##STR2## B is ##STR3## R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen, amino, nitro, halogen, lower-alkly or lower-alkoxy. R.sup.4, R.sup.5 and R.sup.6 are independently hydrogen, nitro, halogen, lower-alkyl, lower-alkoxy, cyano, trifluoromethyl, amino, lower-alkylamino or di-lower-alkylamino. R.sup.7, R.sup.2 and R.sup.9 are independently hydrogen, amino or nitro.

Abstract: The present invention pertains to a process for the coproduction of methanol and dimethyl ether (DME) directly from a synthesis gas in a single step (hereafter, the "single step DME process"). In this process, the synthesis gas comprising hydrogen and carbon oxides is contacted with a dual catalyst system comprising a physical mixture of a methanol synthesis catalyst and a methanol dehydration catalyst. The present invention is an improvement to this process for providing an active and stable catalyst system. The improvement comprises the use of an aluminum phosphate based catalyst as the methanol dehydration catalyst. Due to its moderate acidity, such a catalyst avoids the coke formation and catalyst interaction problems associated with the conventional dual catalyst systems taught for the single step DME process.

Abstract: Compounds of Formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

Abstract: There is disclosed a process for producing a glycidyl ester of acrylic acid or methacrylic acid which comprises the steps of neutralizing acrylic acid or methacrylic acid with a carbonate or a bicarbonate of an alkali metal in an excess amount of epichlorohydrin while an oxygen-containing gas is blown into the liquid reaction system; subjecting water formed by the neutralization and epichlorohydrin to azeotropic distillation to discharge them outside the reaction system and to form an alkali metal salt of acrylic acid or methacrylic acid; adding a quaternary ammonium salt as a catalyst to the reaction system to react the alkali metal salt of the acid with the epichlorohydrin and thus synthesize the glycidyl ester of the acid; cooling the liquid reaction product while recovering part of the excess epichlorohydrin under reduced pressure; adding aqueous solution of an alkali hydroxide to the liquid reaction product to separate into aqueous layer and organic layer; adding a catalyst deactivator to the organic pha

Abstract: The present invention relates to the simultaneous manufacture of difluoromethane (F32) and 1,1,1,2-tetrafluoroethane (F134a) by pyrolysis of chlorodifluoromethane in the presence of hydrogen, working at a temperature above 500.degree. C. in the absence of any catalyst or metal surface. Depending on the operating conditions chosen, this process also makes it possible predominantly to manufacture either F134a or F32.

Abstract: A silicone oil-based anhydrous cosmetic or dermatological anhydrous composition having a homogeneous fatty phase wherein said fatty phase contains a silicone oil having the formula ##STR1## wherein R represents alkyl having 1 to 30 carbon atoms, aryl or aralkyl,n represents a whole number between 0 and 100, andm represents a whole number between 0 and 100, provided that the sum of n+m is between 1 and 100; and(ii) a wax in an amount ranging from 3 to 50 percent by weight based on the total weight of said fatty phase having a melting point between 50.degree. and 135.degree. C., comprising at least polymer having a molecular weight between 200 and 1,500 and selected from ethylene homopolymers and copolymers, and a monomer having the formula:CH.sub.2 .dbd.CH--R' (II)whereinR' represents alkyl having 1 to 30 carbon atoms, aryl or aralkyl.

Abstract: Compounds of the formula ##STR1## where R.sub.1 and R.sub.2, independently are alkyl groups having 2 to 8 carbons; R.sub.3 is hydrogen or lower alkyl; X is S, O or N--R.sub.4 where R.sub.4 is hydrogen or lower alkyl; Y is phenyl or pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, and pyrazinyl; A is (CH.sub.2).sub.n where n is 0-5, or lower branched chain alkyl, alkenyl having 2 to 6 carbons and 1 or 2 double bonds, alkynyl having 2 to 6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a salt thereof, COOR.sub.5, CONR.sub.6 R.sub.7, --CH.sub.2 OH, CH.sub.2 OR.sub.8, CH.sub.2 OCOR.sub.8, CHO, CH(OR.sub.9).sub.2, CHOR.sub.10 O, --COR.sub.11, CR.sub.11 (OR.sub.9).sub.2, or CR.sub.11 OR.sub.10 O, where R.sub.5 is alkyl of 1 to 10 carbons, or cycloalkyl of 5 to 10 carbons, or R.sub.5 is phenyl or lower alkylphenyl, R.sub.6 and R.sub.7 independently are hydrogen, alkyl of 1 to 10 carbons, or cycloalkyl of 5 to 10 carbons, or phenyl or lower alkylphenyl, R.sub.

Abstract: Disclosed is a novel integrated process for production of cyclic esters which includes recovery of starting materials, such as lactic acid from a dilute aqueous lactic acid-containing solution, by solvent extraction. The starting materials are then formed into cyclic esters by removal of water wherein the concentration of higher molecular weight oligomers is maintained below about 20 wt % of the reaction composition. The process further includes providing a recovery solvent for the reaction composition and separating the cyclic esters from the starting materials and higher molecular weight oligomers by liquid-liquid equilibrium separation. The present invention is further directed toward independent novel unit operations of the overall process. The present invention provides for the efficient production and recovery of cyclic esters due to integration of the various unit operations by use of appropriate solvents and recycle streams.

Abstract: Alkenes are prepared by partial hydrogenation of alkynes in the liquid phase over palladium catalysts by a process which comprisesA. using a fixed-bed catalyst which is obtainable by heating the preferably metallic carrier in the air, cooling, coating under reduced pressure with metallic palladium, suitable molding and processing to a monolithic catalyst elements andB. adding from 10 to 180 ppm of CO to the hydrogen used for the hydrogenation.

Abstract: This invention provides a phosphoric diester of formula (I) which is available on di-esterification of phosphoric acid with L-ascorbic acid involving its 5-hydroxyl group and tocopherol involving its hydroxyl group or a pharmacologically acceptable salt thereof. ##STR1## The compound of the invention can be used with advantage as an antioxidant (radical-scavenging) agent and a prophylactic and therapeutic agent for ischemic organ disorders (e.g. myocardial infarction, heart failure, arrhythmia, cerebral infarction, stroke (cerebral apoplexy), renal failure, etc.).

Abstract: The present invention provides:a process for producing an alkali metal salt of an arylmercaptan compound, represented by general formula (3): ##STR1## which process comprises reacting a disulfide compound represented by general formula: ##STR2## with a hydroxide of an alkali metal M.sup.1 in the presence of a sulfur compound represented by general formula (2):H.sub.(2-i) S(M.sup.1).sub.i (2)a process for producing an alkoxycarbonylalkylthioaryl compound represented by general formula (5): ##STR3## which process comprises reacting the above-mentioned alkalimetal salt of an arylmercaptan compound with a halogenofattyacid ester compound represented by general formula (4):X.sup.1 R.sup.2 COOR.sup.3 (4)at pH 7-10; anda process for producing the above-mentioned alkoxycarbonylalkylthioaryl compound, which process comprises reacting the above-mentioned disulfide compound with the above-mentioned hydroxide of an alkali metal M.sup.

Abstract: A process for the preparation of an oxirane compound by reacting an olefinically unsaturated hydrocarbon with an organic hydroperoxide, in the presence of a catalyst comprising a titanasilsesquioxane of the general formula TiLR.sub.7 Si.sub.7 O.sub.12 and the structural formula ##STR1## wherein R is chosen from the group of cyclopentyl, cyclohexyl and cycloheptyl and L is chosen from the group of alkyl, cycloalkyl, alkylaryl, alkoxy, aryloxy, siloxy, amido and OH.